Imperial Brands announced a £1.5 billion share buyback program alongside fiscal 2026 guidance that projects adjusted operating profit growth of 3% to 5%, high-single-digit adjusted earnings per share growth, and £2.2 billion in free cash flow.

The buyback—roughly 68% of the projected free cash flow—signals the company is prioritizing shareholder returns over aggressive reinvestment in next-generation products like nicotine pouches, where competitors including BAT and Philip Morris International have poured billions into manufacturing, R&D, and market expansion.

What the numbers mean for nicotine pouches

Imperial's next-gen portfolio includes the Zone X nicotine pouch brand, which has seen limited international rollout compared to BAT's VELO or PMI's ZYN. The £2.2 billion free cash flow figure represents the total cash available after capital expenditures—money that could fund new pouch production lines, flavor R&D, or market entry in high-growth regions like the U.S. or Scandinavia.

By committing £1.5 billion to buybacks, Imperial is effectively choosing to return capital rather than match the scale of investment rivals have made in oral nicotine. For context, PMI spent over $1 billion acquiring ZYN manufacturer Swedish Match in 2022, while BAT has consistently expanded VELO capacity across multiple continents.

The 3% to 5% operating profit growth guidance suggests Imperial expects its core tobacco business to remain stable, but the high-single-digit EPS growth target relies heavily on share count reduction from the buyback rather than revenue expansion in newer categories.

Imperial's pouch strategy

Imperial has positioned Zone X as a "premium" nicotine pouch offering in select European markets, but the brand lacks the distribution footprint or marketing spend of category leaders. The company has not disclosed Zone X-specific revenue or volume figures, and the product remains absent from key growth markets including the United States, where ZYN alone generated over $2 billion in net revenues for PMI in 2024.

The FY26 guidance does not break out next-gen product targets, meaning pouch growth—if any—is bundled into the broader 3-5% operating profit range alongside traditional tobacco, vaping, and heated tobacco products.

What's next

Imperial's fiscal 2026 runs through September 2026. The £1.5 billion buyback will execute over that period, with the company expecting to deliver the £2.2 billion free cash flow target assuming stable combustible volumes and no major regulatory disruptions.

For pouch watchers, the key question is whether Imperial will shift capital allocation in future years as oral nicotine margins improve—or whether the company has effectively conceded the category to BAT, PMI, and independent players like Swedish Match (pre-acquisition) and Altria's on! brand.

---

SOURCES
Tobacco Reporter